Conference Correspondent
News, views, and coverage of important topics and discussions from oncology conferences and events.
Myelofibrosis is associated with poor overall survival and clinical outcomes. Treatment with ruxolitinib earlier in disease course shows promise for improving symptoms and overall survival.
Read More ›
First-line treatment with relatlimab plus nivolumab demonstrated a statistically significant progression-free survival benefit compared with nivolumab monotherapy in patients with advanced melanoma. Read More ›
In a 6.5-year update of CheckMate-067, durable improvements in overall survival, progression-free survival, and objective response rate were observed with nivolumab plus ipilimumab over nivolumab alone as first-line therapy in patients with advanced melanoma, with no new safety signals. Read More ›
Neoadjuvant and adjuvant treatment with nivolumab plus relatlimab for resectable stage III melanoma achieved high pathologic complete response and major pathologic response rates. Read More ›
Dual immunotherapy provides significant and durable benefits as first-line treatment and as neoadjuvant therapy in advanced melanoma. Read More ›
MRD status at the time of allogeneic stem-cell transplantation and the number of remissions prior to transplant were shown to be important independent prognostic factors in patients with AML. Read More ›
Addition of venetoclax to FLAG-IDA yielded high minimal residual disease–negative composite complete response rates in newly diagnosed patients with AML, accompanied by a favorable safety profile. Read More ›
The phase 3 AGILE study demonstrated that ivosidenib + azacitidine therapy provided significant survival benefit compared with placebo plus azacitidine in patients with newly diagnosed IDH1 mutation–positive AML who were ineligible for intensive chemotherapy. Read More ›
AML patients who underwent allogeneic stem-cell transplantation from unrelated donors while in their second complete remission with post-transplant cyclophosphamide had similar outcomes to those who underwent transplantation while in first complete remission. Read More ›
In the first-in-human phase 1/2 AUGMENT 101 study, SNDX-5613 demonstrated an acceptable safety profile and promising antileukemic activity in patients with heavily pretreated relapsed/refractory MLL-rearranged and NPM1-mutated acute leukemias. Read More ›